Stockscreener 앱 받기
9.87
0.00%
0.00
시간 외 거래:
9.88
0.01
+0.10%
Drugs Made In America Acquisition Ii Corp 주식(DMII)의 최신 뉴스
Pfizer Inc. - Britannica
Layoff Tracker: Pfizer, Geron Downsize To Streamline Costs - BioSpace
Aug Movers: Is Drugs Made In America Acquisition Corp stock a top momentum playWeekly Volume Report & Free Technical Pattern Based Buy Signals - moha.gov.vn
What analysts say about Drugs Made In America Acquisition Corp stockDividend Yield Trends & Exceptional Profit Portfolio - earlytimes.in
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company - Yahoo Finance
Hims & Hers acquires Livewell in Canada in anticipation of generic Ozempic - The Globe and Mail
Drugs Made In America Appoints New CFO - MSN
Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025 - Markets Financial Content
Prescription Drug Costs - Britannica
Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing DealsWhat Investors Need To Know - Seeking Alpha
BMK Pharma To Open $50M U.S. HQ and Pharmaceutical Facility in Allen - Dallas Innovates
CVS Pharmacy Completes Acquisition of Rite Aid Assets - Progressive Grocer
FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance - statnews.com
Trump Wants to Overhaul Drug Sales. A Company Tied to His Son Stands to Benefit | World News - Hindustan Times
Canadian tech helped U.S. strike alleged Venezuelan drug boats: report - CBC
Drugs Made In America Acquisition II Corp. completes $500 million IPO and private placement - Investing.com
Drugs Made In America Acquisition II Corp. closes $500 million IPO - Investing.com
Drugs Made In America $500M In IPO Marks 2025’s Biggest SPAC Debut - USA Herald
Celltrion buys Eli Lilly’s New Jersey plant for $330 million - The Korea Economic Daily Global Edition
Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis - The New York Times
$10B Domestic Drug Production Deal: PharmAGRI and Tesla to Deploy 10,000 Robots for US Prescription Drugs - Stock Titan
10,000 Tesla Robots to Power US Pharma Manufacturing: Bright Green's Merger Creates Sovereign Drug Platform - Stock Titan
U.S. Drugmakers Warn White House of Chaos as Trump Weighs Curbs on China - The New York Times
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company - Yahoo Finance
CSL's Venofer finally faces generic competition as FDA clears copycats from Viatris, Sandoz and Amphastar - Fierce Pharma
UPDATED: Most expensive drugs in the US in 2025 - Fierce Pharma
Updated: AstraZeneca reports revenue growth, pipeline tweaks as it ponders price cuts, direct-to-patient sales - Endpoints News
Pharmalittle: We're reading about Sarepta resisting FDA over Elevidys, agency naming top drug regulator, and more - statnews.com
US FDA approves Regeneron's blood cancer therapy - Reuters
US pharma bets big on China to snap up potential blockbuster drugs - Reuters
Markets News, May 12, 2025: Stocks Surge After US, China Agree to Slash Tariffs; Dow Jumps Nearly 1,200 Points as Amazon, Apple, Nike Soar - Investopedia
The top 20 pharma companies by 2024 revenue - Fierce Pharma
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - GlobeNewswire
The top 10 drugs losing US exclusivity in 2025 - Fierce Pharma
7 Best Weight Loss Drug Stocks to Buy in 2025 - US News Money
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Announces Advisory Team - GlobeNewswire
Popular cannabis brand declares Chapter 11 bankruptcy - thestreet.com
Hims & Hers Acquires US-based Peptide Facility - Hims Investor Relations
SPAC Alert: Key Trading Change Coming for Drugs Made In America UnitsWhat Investors Should Track - Stock Titan
U.S. investors, Big Pharma race to find new medicines in China - CNBC
What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing - ProPublica
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - Fierce Pharma
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential - Fortune
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - renaissancecapital.com
Drugs Made In America Acquisition Corp. Completes $200 Million IPO on Nasdaq - Nasdaq
Drugs Made In America SPAC Nets $200M To Buy Pharma Biz - Law360
Top 10 most anticipated drug launches of 2025 - Fierce Pharma
Danone’s yogurt sales surge among US consumers using GLP-1 drugs - Food Dive
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims - Newsweek
How Trump’s Greenland demands could impact Ozempic costs - thehill.com
The top 10 biopharma M&A deals of 2024 - Fierce Pharma
2025 forecast: As companies rush to radiopharmaceuticals for oncology, what's next? - Fierce Pharma
Trump’s Denmark Tariff Threat Means New Uncertainty for Ozempic Drugmaker Novo Nordisk - Barron's
2024 drug approvals: Small companies loom large with several key FDA nods - Fierce Pharma
Bright Green enters into restructuring security agreement with Lynn Stockwell - Yahoo Finance
LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO. - Yahoo Finance
Ranked: The Biggest Health Insurance Giants in America - Visual Capitalist
7 Companies Owned by Pfizer - Investopedia
Top 10 Asthma Drug Companies | Provides Best Medicines - Market.us Media
FTC’s watchdog role in pharma mergers: Road bumps and the way forward | United States | Global law firm - Norton Rose Fulbright
BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda - Fierce Pharma
Vanguard Group Inc's Strategic Acquisition of Arvinas Inc Shares - Yahoo Finance
The Mars-Kellanova merger bolsters them against 2 big threats—inflation and Ozempic - Fortune
We bought what’s needed to make millions of fentanyl pills–for $3,600 - Reuters
Drug giants eye China for deals despite growing Sino-US tensions - Reuters
China-made injectable PD-L1 drug flunks pivotal trial, forcing US partner to seek strategic options - Fierce Pharma
Top 10 smartest deals in biopharma - Fierce Biotech
CEO UPDATE - GlobeNewswire
Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs (Published 2024) - The New York Times
Eli Lilly and Co. | Pharmaceuticals, Biomedical Research, & Company - Britannica
0.20%
자본화:
|
볼륨(24시간):